GELS Overview

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

Wall Street analysts forecast GELS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GELS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Gelteq Ltd revenue for the last quarter amounts to 0.00 USD, decreased

Gelteq Ltd. EPS for the last quarter amounts to -0.12 USD, increased 20.00

Gelteq Ltd (GELS) has 7 emplpoyees as of March 02 2026.

Today GELS has the market capitalization of 8.29M USD.